Zaltoprofen

Enzymes (3)Biointeractions (3)

Identification

Name
Zaltoprofen
Accession Number
DB06737
Type
Small Molecule
Groups
Experimental
Description

A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.

Structure
Thumb
3D
Similar Structures
Synonyms
  • Zaltoprofen
  • Zaltoprofene
  • Zaltoprofeno
  • Zaltoprofenum
External IDs
CN 100 / CN-100 / ZC 102
International/Other Brands
Borbit (Yoshindo) / Peleton (Towa Yakuhin) / Peon (Zeria Shinyaku) / Salafapinon (Choseido Pharmaceutical) / Soleng (Kyorin Rimedio) / Soleton (CJ Cheiljedang) / Soluirubin (Taiyo Pharmaceutical) / Zaltoprofen Tatsumi Kagaku (Tatsumi Kagaku) / Zatferon (Sawai Seiyaku) / Zyrogen (Yoo Young)
Categories
UNII
H8635NG3PY
CAS number
74711-43-6
Weight
Average: 298.36
Monoisotopic: 298.066365485
Chemical Formula
C17H14O3S
InChI Key
MUXFZBHBYYYLTH-UHFFFAOYSA-N
InChI
InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
IUPAC Name
2-{10-oxo-2-thiatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-6-yl}propanoic acid
SMILES
CC(C(O)=O)C1=CC=C2SC3=C(C=CC=C3)C(=O)CC2=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with (4R)-limonene.
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with (S)-Warfarin.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 16-Bromoepiandrosterone.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with 4-hydroxycoumarin.
5-androstenedioneThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 5-androstenedione.
AbacavirZaltoprofen may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Abciximab.
AbirateroneThe metabolism of Zaltoprofen can be decreased when combined with Abiraterone.
Food Interactions
Not Available

References

General References
  1. Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13. [PubMed:16473424]
External Links
KEGG Drug
D01547
PubChem Compound
5720
PubChem Substance
347827786
ChemSpider
5518
ChEBI
32306
ChEMBL
CHEMBL1765291
Wikipedia
Zaltoprofen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusTreatmentInjuries, Whiplash1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP3.55ALOGPS
logP3.76ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)3.67ChemAxon
pKa (Strongest Basic)-7.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity83.69 m3·mol-1ChemAxon
Polarizability31.16 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzothiepins. These are compounds containing a dibenzothiepin moiety, which consists of two benzene connected by a thiepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiepins
Sub Class
Dibenzothiepins
Direct Parent
Dibenzothiepins
Alternative Parents
Diarylthioethers / Aryl alkyl ketones / Vinylogous thioesters / Benzenoids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Dibenzothiepin / Diarylthioether / Aryl thioether / Aryl ketone / Aryl alkyl ketone / Benzenoid / Vinylogous thioester / Ketone / Thioether / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Details1. UDP-glucuronosyltransferase 2B7
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Details2. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Furuta S, Akagawa N, Kamada E, Hiyama A, Kawabata Y, Kowata N, Inaba A, Matthews A, Hall M, Kurimoto T: Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Br J Clin Pharmacol. 2002 Sep;54(3):295-303. [PubMed:12236850]
Details3. Prostaglandin G/H synthase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Drug created on August 31, 2010 14:54 / Updated on October 21, 2018 20:34